File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A comparison study of different PCR assays in measuring circulating plasma Epstein-Barr virus DNA levels in patients with nasopharyngeal carcinoma

TitleA comparison study of different PCR assays in measuring circulating plasma Epstein-Barr virus DNA levels in patients with nasopharyngeal carcinoma
Authors
Issue Date2005
Citation
Clinical Cancer Research, 2005, v. 11, n. 16, p. 5700-5707 How to Cite?
AbstractPurpose: To compare the performance of three PCR assays in measuring circulating Epstein-Barr virus (EBV). DNA levels in nasopharyngeal carcinoma patients and to confirm its prognostic significance. Experimental Design: Plasma from 58 newly diagnosed nasopharyngeal carcinoma patients were collected before, during, and every 3 to 6 months after radiotherapy. EBV DNA levels were determined by real-time quantitative PCR using primer/probe sets for polymerase-1 (Pol-1), latent membrane protein 2 (Lmp2), and BamHI-W. Pretreatment levels from the three assays were correlated with each other and serial measurements from the Pol-1 assay were correlated with clinical variables. Results: Pol-1 was more accurate than BamHI-W in predicting EBV DNA concentrations in cell lines. Ofthe three assays, BamHI-W yielded the highest concentrations followed by Pol-1 in plasmas (n = 23). The correlation coefficient was 0.99 (P < 0.0001) for Pol-1 and Lmp2, 0.66 (P < 0.0001) for Pol-1 and BamHI-W, and 0.55 (P < 0.0001) for BamHI-W and Lmp2. Elevated pretreatment DNA levels as detected by Pol-1 were correlated with advanced nodal stage (P = 0.04) and overall stage (P = 0.028). There was no correlation between pretreatment EBV DNA levels and freedom-from-relapse or overall survival; however, there was a significant correlation between posttreatment levels and these variables. The 2-year freedom-from-relapse and overall survival rates were 92% and 94% for patients with undetectable, and 37% and 55% for those with detectable, posttreatment levels (P < 0.0001 and P < 0.002). Conclusions: The three PCR assays yielded similar results in detecting EBV DNA in plasmas. The Pol-7-detected posttreatment EBV DNA level was the strongest predictor for treatment outcomes. © 2005 American Association for Cancer Research.
Persistent Identifierhttp://hdl.handle.net/10722/213894
ISSN
2015 Impact Factor: 8.738
2015 SCImago Journal Rankings: 5.314

 

DC FieldValueLanguage
dc.contributor.authorLe, Quynh Thu-
dc.contributor.authorJones, Carol D.-
dc.contributor.authorYau, Tsz Kok-
dc.contributor.authorShirazi, Haider A.-
dc.contributor.authorWong, Priscilla H.-
dc.contributor.authorThomas, Ella N.-
dc.contributor.authorPatterson, Bruce K.-
dc.contributor.authorLee, Anne W M-
dc.contributor.authorZehnder, James L.-
dc.date.accessioned2015-08-19T13:41:07Z-
dc.date.available2015-08-19T13:41:07Z-
dc.date.issued2005-
dc.identifier.citationClinical Cancer Research, 2005, v. 11, n. 16, p. 5700-5707-
dc.identifier.issn1078-0432-
dc.identifier.urihttp://hdl.handle.net/10722/213894-
dc.description.abstractPurpose: To compare the performance of three PCR assays in measuring circulating Epstein-Barr virus (EBV). DNA levels in nasopharyngeal carcinoma patients and to confirm its prognostic significance. Experimental Design: Plasma from 58 newly diagnosed nasopharyngeal carcinoma patients were collected before, during, and every 3 to 6 months after radiotherapy. EBV DNA levels were determined by real-time quantitative PCR using primer/probe sets for polymerase-1 (Pol-1), latent membrane protein 2 (Lmp2), and BamHI-W. Pretreatment levels from the three assays were correlated with each other and serial measurements from the Pol-1 assay were correlated with clinical variables. Results: Pol-1 was more accurate than BamHI-W in predicting EBV DNA concentrations in cell lines. Ofthe three assays, BamHI-W yielded the highest concentrations followed by Pol-1 in plasmas (n = 23). The correlation coefficient was 0.99 (P < 0.0001) for Pol-1 and Lmp2, 0.66 (P < 0.0001) for Pol-1 and BamHI-W, and 0.55 (P < 0.0001) for BamHI-W and Lmp2. Elevated pretreatment DNA levels as detected by Pol-1 were correlated with advanced nodal stage (P = 0.04) and overall stage (P = 0.028). There was no correlation between pretreatment EBV DNA levels and freedom-from-relapse or overall survival; however, there was a significant correlation between posttreatment levels and these variables. The 2-year freedom-from-relapse and overall survival rates were 92% and 94% for patients with undetectable, and 37% and 55% for those with detectable, posttreatment levels (P < 0.0001 and P < 0.002). Conclusions: The three PCR assays yielded similar results in detecting EBV DNA in plasmas. The Pol-7-detected posttreatment EBV DNA level was the strongest predictor for treatment outcomes. © 2005 American Association for Cancer Research.-
dc.languageeng-
dc.relation.ispartofClinical Cancer Research-
dc.titleA comparison study of different PCR assays in measuring circulating plasma Epstein-Barr virus DNA levels in patients with nasopharyngeal carcinoma-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1158/1078-0432.CCR-05-0648-
dc.identifier.pmid16115906-
dc.identifier.scopuseid_2-s2.0-23844440912-
dc.identifier.hkuros266071-
dc.identifier.volume11-
dc.identifier.issue16-
dc.identifier.spage5700-
dc.identifier.epage5707-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats